Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Inclusion Criteria

• •All patients must have histologically or cytologically documented non-small cell carcinoma of the lung (adenocarcinoma, large cell, squamous, or mixtures of these types)
• •Patients with stage IV disease are eligible
• •Documentation of PS 2 must be noted on form C-1392
• •Patients must have measurable or non-measurable disease
• •Measurable disease (target lesions): lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan
• •Non-measurable disease (non-target lesions): all other lesions, including small lesions (longest diameter \< 20 mm with conventional techniques or \< 10 mm with spiral CT scan) and truly nonmeasurable lesions; lesions that are considered non-measurable include the following:
• •* Bone lesions
• •* Ascites
• •* Pleural/pericardial effusion
• •* Lymphangitis cutis/pulmonis
• •* Abdominal masses that are not confirmed and followed by imaging techniques
• •* Cystic lesions
• •No prior systemic treatment for advanced NSCLC is permitted; prior treatment for early-stage disease (adjuvant) or for locally-advanced stage III disease is allowed if completed at least 12 months prior to registration
• •Patients must have recovered (all toxicities ≤ grade 1) from prior surgery and/or radiotherapy
• •No prior therapy which specifically and directly targets the EGFR pathway
• •No prior severe infusion reactions to a monoclonal antibody
• •No ≥ grade 2 peripheral neuropathy
• •Non-pregnant and non-nursing
• •No concurrent treatment with any other investigational therapy
• •Granulocytes ≥ 1,500/μl
• •Platelets ≥ 100,000/μl
• •Serum creatinine ≤ ULN
• •Bilirubin ≤ ULN
• •AST ≤ ULN